Study with Lab Mice Shows Reversal of Osteoporosis

According to the National Osteoporosis Foundation, approximately 54 million Americans have osteoporosis or low bone mass, placing them at risk for osteoporosis. Approximately one in two women age 50 and older will break a bone due to osteoporosis and the complications can be serious. The disease is responsible for two million broken bones and $19 billion in healthcare costs each year. Experts expect that number will reach $25.3 billion by 2025. Osteoporosis is a serious problem and thanks to a study from the Children's Medical Research Institute (CRI) at the University of Texas Southwestern, a new cure could be on the horizon.

Scientists at UT Southwestern’s CRI gave daily doses of Teriparatide (PTH), a drug approved for limited use in osteoporosis treatment, to female mice modeling osteoporosis in postmenopausal women. They also gave recombinant Osteolectin, a bone-forming growth factor that promotes the formation of new bone from skeletal stem cells in the bone marrow, to mice without ovaries. Both groups of mice exhibited increased bone volume and reversed any loss that occurred. This research could have big implications for other regenerative medicine-centered studies.

To learn more about this study, please click here.